Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Cancer Res. 2020 Mar 3;80(11):2094–2100. doi: 10.1158/0008-5472.CAN-19-3126

Figure 1: ATM loss in prostate cancer.

Figure 1:

A. Copy-number analysis of TCGA prostate adenocarcinoma (PRAD) cohort shows that a segment of chromosome 11q22.3 which includes the ATM gene is focally lost (q=2.6e-4). B. Heterozygous loss, homozygous loss, and frameshift/nonsense mutations in ATM and other tumor suppressor genes are more frequent in mCRPC than in primary prostate tumors. C. ATM gene expression in normal versus tumor tissue across several TCGA tumor types shows a subset of tumors with low ATM transcript levels (denoted by gray arrow). D. ATM gene expression is decreased in prostate tumors compared to normal prostate tissue, and tumors with heterozygous or homozygous ATM deletion have significantly lower ATM levels than tumors without ATM deletion. mCRPC, metastatic castration-resistant prostate cancer. Loc., localized prostate cancer.